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Frameshift and nonsense mutations are common in tumors with microsatellite instability, and mRNAs from these
mutated genes have premature termination codons (PTCs). Abnormal mRNAs containing PTCs are normally degraded
by the nonsense-mediated mRNA decay (NMD) system. However, PTCs located within 50–55 nucleotides of the last
exon–exon junction are not recognized by NMD (NMD-irrelevant), and some PTC-containing mRNAs can escape from
the NMD system (NMD-escape). We investigated protein expression from NMD-irrelevant and NMD-escape PTC-
containing mRNAs by Western blotting and transfection assays. We demonstrated that transfection of NMD-irrelevant
PTC-containing genomic DNA of MARCKS generates truncated protein. In contrast, NMD-escape PTC-containing
versions of hMSH3 and TGFBR2 generate normal levels of mRNA, but do not generate detectable levels of protein.
Transfection of NMD-escape mutant TGFBR2 genomic DNA failed to generate expression of truncated proteins,
whereas transfection of wild-type TGFBR2 genomic DNA or mutant PTC-containing TGFBR2 cDNA generated expression
of wild-type protein and truncated protein, respectively. Our findings suggest a novel mechanism of gene expression
regulation for PTC-containing mRNAs in which the deleterious transcripts are regulated either by NMD or translational
repression.
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Introduction
A subset of colorectal carcinomas exhibit a molecular
phenotype commonly referred to as high microsatellite
instability (MSI-H) [1]. The microsatellite instability (MSI)
pathway begins with the inactivation of one of a group of
genes responsible for DNA nucleotide mismatch repair
(MMR), which leads to extensive mutations in both repetitive
and non-repetitive DNA sequences [2–4]. The mechanism of
tumorigenesis in MSI-H tumors is thought to involve frame-
shift mutations of microsatellite repeats within the coding
regions of affected genes, and the inactivation of these genes
is believed to contribute directly to tumor development and
progression [5,6]. The frameshift mutations observed in the
affected genes are expected to generate previously unde-
scribed amino acid sequences in the C-terminal part of the
respective proteins (Figure S1). If abnormal mRNAs and
proteins are generated from the frameshift-mutated genes,
tumor-speciﬁc antigen may be generated. High peritumoral
lymphocytic inﬁltration and a relatively good prognosis have
been reported in MSI-H tumors [7,8].
One of the important consequences of frameshift muta-
tions is the formation of premature termination codons
(PTCs). In mammalian cells, mRNAs containing a PTC due to
a nonsense mutation or a frameshift mutation are recognized
and degraded by nonsense-mediated mRNA decay (NMD),
thus eliminating the production of the potentially deleterious
truncated proteins [9,10]. NMD of mRNAs carrying PTCs is
mediated through the recognition of the PTC by its position
relative to the 39-most last exon–exon junction. As a general
rule, mammalian transcripts that contain a PTC more than
50–55 nucleotides (nt) upstream of the last exon–exon
junction will be subjected to NMD [11,12].
Although PTC formation in frameshift mutation-derived
mRNAs and their subsequent degradation through NMD is
widely accepted, PTCs located within 50–55 nt or down-
stream of the last exon–exon junction are not recognized by
NMD (NMD-irrelevant), and some mRNAs with PTCs more
than 50–55 nt upstream of their last exon–exon junction are
not degraded by NMD (NMD-escape) [13,14]. In MSI-H
tumors, several NMD-sensitive or NMD-escape PTC-contain-
ing mRNAs have been reported. A previous study compared
the total mRNAs of affected genes from various cell lines [15].
However, this study did not differentiate the proportion of
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PLoS BIOLOGYwild-type and mutant mRNAs, and did not conﬁrm the
mutant mRNAs through sequencing. This study also did not
consider that the amount of mRNA from the affected genes
might vary between cell lines. Moreover, the expression
statuses and biological effects of the NMD-escape PTC-
containing mRNAs are essentially unknown.
In order to clarify the protein expression status of affected
genes with frameshift mutations and the role of NMD in these
mutated genes, we selected MSI-H cancers as a model system
because these cancers have accumulated genes with frame-
shift mutations, and the mRNAs expected from these mutated
genes contain PTCs. We analyzed the expression of 20 mutant
mRNAs from 12 genes and evaluated their regulation along
with the regulation of associated proteins. We demonstrate
that some PTC-containing mRNAs escaped from NMD, but
did not generate truncated proteins, indicating that PTC-
containing transcripts can be regulated either by NMD or
translational repression.
Results
Genes with Frameshift Mutations Form PTCs in Their
mRNAs
To examine the effect of NMD on the affected genes with
frameshift mutations in MSI-H tumors, we selected 12 genes
from MSI-H tumors based on the reported frameshift
mutation frequencies greater than 30% (ABCF1, ACVR2,
hMSH3, hMSH6, hRad50, MARCKS, PRKWNK1, RFC3, SEC63,
TAF1B, TCF-4, and TGFBR2). We used genome sequencing of
these 12 genes to identify frameshift mutation status. In these
12 genes, we identiﬁed 20 frameshift mutations that fell into
three categories: 12 mutations were single base pair (bp)
deletions, six were 2-bp deletions, and two were single bp
insertions in coding mononucleotide repeats (cMNR) (Table
S1). All 20 frameshift mutations of the 12 genes resulted in
mRNAs containing a PTC (Table 1).
Identification of NMD-Escape PTC-Containing mRNAs
We analyzed mRNA expression of the 12 genes by reverse
transcriptase PCR (RT-PCR) in seven MMR-deﬁcient
(LS174T, HCT-8, SNU C2A, SNU C4, DLD-1, HCT116, and
LOVO) and three MMR-proﬁcient (NCI-H508, SW480, and
HT29) colorectal cancer cell lines. Primers were designed to
contain at least one exon–exon junction region and to
amplify the coding repeat sequences (Table S2). Of the 20
Table 1. Expressions of Frameshift Mutant mRNAs in MMR-Deficient Colorectal Cancer Cell Lines
Class of PTC-
Containing mRNA
Gene
Name
Type of
Frameshift
Mutation
a
Type of
Repeat
Position of
Mononucleotide
Repeat
Position of
PTC
Distance from
Last Exon–
Exon Junction
Detection of mRNA
(Detected No. of Mutant mRNA/
No. of Frameshift Mutation)
NMD-sensitive ABCF1  1 A10 312 497 1,853 0/3
 2 A10 312 359 1,990 0/1
hMSH6  1 C8 3,341 3,352 735 0/2
þ1 C8 3,341 3,361 728 0/2
hRad50  1 A9 2,544 2,590 1,548 0/4
þ1 A9 2,544 2,566 1,574 0/1
PRKWNK1  1 A10 1739 1,777 5,053 0/3
RFC3  1 A10 317 398 562 0/6
SEC63  1 A10 1776 1,864 454 0/4
 2 A10 1776 1,852 465 0/1
NMD-escape hMSH3  1 A8 1,130 1,229 2,061 2/2
TAF1B  1 A11 285 369 1,293 1/1
 2 A11 285 300 1,361 4/4
TGFBR2  1 A10 709 819 1,039 6/6
 2 A10 709 723 1,134 1/1
NMD-irrelevant ACVR2  1 A8 1,466 1,484 25 7/7
 2 A8 1,466 1,526  18
b 1/1
MARCKS  1 A10 823 865 Last exon
c 4/4
 2 A10 823 913 Last exon
c 1/1
TCF-4  1 A9 1,684 1,757 Last exon
c 4/4
aThe negative ( ) and positive (þ) signs indicate deletion and insertion, respectively, of base pairs.
bFrameshift mutation-induced PTC is located distal to the last exon–exon junction.
cMononucleotide repeat and PTC located at the last exon.
doi:10.1371/journal.pbio.0050109.t001
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Author Summary
A class of mutations found in many cancers introduces aberrant
termination signals during the synthesis of mRNA. In mammalian
cells, abnormal mRNAs containing premature termination codons
(PTCs) are normally degraded by a process called nonsense-
mediated mRNA decay (NMD), thus avoiding potentially deleterious
effects from abnormal protein production. However, some PTC-
containing mRNAs are known to escape from NMD. By screening
protein expression from genes with serious mutations in colon
cancers, we confirmed that PTC-containing mRNAs of some genes
escape from NMD. However, their abnormal proteins were not
found in the tumor cells. To study the means by which these
proteins were regulated, we transfected separate cell lines with
NMD-escape mutant genomic DNA, wild-type genomic DNA, and
mutant cDNA. We found that truncated proteins are not generated
from the NMD-escape mutant genomic DNA, whereas wild-type
protein and truncated protein were generated normally. These
results indicate that the translation of PTC-containing mutant
mRNAs is repressed in the cytoplasm.frameshift mutations in the genomic DNA, mutation-derived
transcripts were detected from ten alleles representing six
genes (hMSH3, TAF1B, TGFBR2, ACVR2, MARCKS, and TCF-
4), whereas ten alleles representing six genes (ABCF1, hMSH6,
hRad50, PRKWNK1, RFC3, and SEC63) did not generate
frameshift mutation-derived transcripts. No differences in
expression of frameshift mutation-derived mRNA were
observed between cell lines. Of the ten transcripts with
frameshift mutations, ﬁve transcripts (representing three
genes: hMSH3, TAF1B, and TGFBR2) had PTCs more than 50–
55 nt upstream of the last exon–exon junction and were
therefore expected to be degraded by NMD but instead
escaped from NMD (NMD-escape). On the other hand, the
ﬁve remaining transcripts (representing three genes: ACVR2,
MARCKS, and TCF-4) had PTCs within 50–55 nt upstream of
the last exon–exon junction and were therefore expected to
be irrelevant to NMD (NMD-irrelevant). Accordingly, the 20
transcripts from 12 genes were classiﬁed as NMD-sensitive,
NMD-escape, and NMD-irrelevant (Table 1).
In order to conﬁrm the effect of NMD on the NMD-
sensitive and NMD-escape PTC-containing mRNAs, we used
RT-PCR and a ribonuclease protection assay (RPA) to analyze
the expression of the target gene mRNAs after treatment with
puromycin, a translation inhibitor. In the ﬁve NMD-escape
alleles that generated detectable frameshift mutation-derived
mRNAs, no expression differences were found after puromy-
cin treatment. In the ten NMD-sensitive alleles that produced
no detectable frameshift mutation-derived mRNAs, mutant
transcripts were detected after puromycin treatment (Figure
S2). We analyzed the amount of two degraded NMD-sensitive
transcripts, hRad50 and hMSH6, by RPA and found a total
loss of mutant transcripts, as evidenced by a 2-fold increase in
hRad50 and hMSH6 products after puromycin treatment. In
contrast, there was no loss of TGFBR2 mutant mRNA, an
NMD-escape transcript, because the amount of product was
unchanged after puromycin treatment (Figure 1).
Next, we evaluated the effect of down-regulating UPF1 or
UPF2, which are key NMD factors, on the stability of the
frameshift mutation-derived mRNAs, hRad50 and hMSH6,
using speciﬁc small interfering RNA (siRNA). Upon the
treatment of luciferase siRNA, expression of the mutation-
derived hRad50 and hMSH6 mRNAs were not detected in the
cell lines with hRad50 and hMSH6 mutations. In contrast,
down-regulating UPF1 or UPF2 abundantly increased the
frameshift mutation-derived mRNAs, as conﬁrmed by RT-
PCR, and sequence analysis. These ﬁndings indicate that
frameshift mutation-derived mRNAs of hRad50 and hMSH6
are recognized and degraded by the NMD system (Figure S3).
Truncated Proteins from NMD-Escape PTC-Containing
mRNAs of hMSH3 Are Not Detected by Western Blotting
In order to determine if the truncated protein products
from PTC-containing mRNAs can be detected, we ﬁrst
performed Western blotting analyses using antibodies direc-
ted against the N-terminus of hRad50, hMSH6, and hMSH3.
Truncated proteins were not detected for the NMD-sensitive
(hRad50 and hMSH6) genes, whereas wild-type proteins were
detected in the cell lines containing the wild-type allele.
These results support the previous ﬁnding that NMD-
sensitive PTC-containing mRNAs are degraded by the NMD
system. In the NMD-escape hMSH3 gene, we detected full-
length hMSH3 proteins in cell lines with no mutations or with
monoallelic mutations in these genes; however, we could not
detect truncated hMSH3 proteins in any of the cell lines
carrying frameshift mutations (Figure 2). The hMSH3 anti-
body detected the truncated proteins from the cell lines
transfected with mutant hMSH3 cDNA, indicating that the
antibodies used in our experiments speciﬁcally react with the
N-terminal region of hMSH3 protein (Figure S4). Further-
more, we could not detect the truncated proteins of hMSH3
genes after treatment with the proteasome inhibitors MG132
or E64 (unpublished data), which excludes the possibility of
rapid degradation of mutated proteins.
Selective Translational Repression of Mutant TGFBR2
following Normal Splicing
We interpreted the failure to detect truncated protein
from the NMD-escape PTC-containing mRNAs as follows: (1)
truncated proteins were generated, but at an amount not
sufﬁcient for detection by Western blotting, (2) truncated
proteins were generated, but then rapidly degraded, or (3)
truncated proteins were not generated from the mutant
mRNA.
To rule out an insufﬁcient amount of endogenous
truncated proteins, we constructed expression plasmids with
NMD-escape PTC-containing genomic DNA or cDNA of
TGFBR2: (1) wild-type cDNA of TGFBR2 (K: TGFBR2(WT)-
cDNA), (2) PTC-containing mutant cDNA of TGFBR2 without
downstream exons and introns (L: TGFBR2( 1)-cDNA), (3)
wild-type TGFBR2 genomic DNA (M: TGFBR2(WT)-splicing),
(4) mutant TGFBR2 genomic DNA with a 1-bp deletion (N:
TGFBR2( 1)-splicing), and (5) mutant TGFBR2 genomic DNA
with a 1-bp deletion and a PTC artiﬁcially located in the last
exon (O: TGFBR2( 1)-irrelevant) (Figure 3A). Among three
NMD-escape PTC-containing mutated genes that we found in
Figure 1. Measurement of Degraded Premature Termination Codon-
Containing mRNAs by RPA Analysis
No loss of TGFBR2 mutant transcripts was noted after puromycin
treatment. In contrast, the amount of hRad50 and hMSH6 mRNA doubled
after puromycin treatment. GAPDH was used for standardization. The
asterisk indicates mutation status of each gene: ( 1) denotes a 1-bp
deletion in the cMNR, (w) denotes no mutation in the cMNR, (þ1)
denotes a 1-bp insertion in the cMNR, and ( 2) denotes a 2-bp deletion
in the cMNR.
doi:10.1371/journal.pbio.0050109.g001
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excluded because of their large size and number of exons,
which result in the failure or inefﬁcient transfection of
genomic DNA.
In all of the constructs described above, the nucleotide
sequences encoding FLAG peptide was introduced immedi-
ately downstream of the initiation codon, which allows for
detection of the encoded proteins by Western blotting. These
vectors were designed to differentiate the effect of spliced
wild-type mRNA, spliced mutant NMD-escape mRNA, and
spliced mutant NMD-irrelevant mRNA in terms of truncated
protein expression. We observed abundant expression of
PTC-containing TGFBR2 mRNA in cell lines transfected with
TGFBR2( 1)-cDNA, TGFBR2( 1)-splicing, and TGFBR2( 1)-
irrelevant (Figure 3B). Cell lines transfected with
TGFBR2(WT)-splicing, TGFBR2( 1)-splicing, and
TGFBR2( 1)-irrelevant showed accurate splicing, and all
normal and mutant mRNA products were conﬁrmed by
sequence analysis (unpublished data). A semi-quantitative
RT-PCR analysis designed to detect exogenous TGFBR2
mRNA showed similar and abundant amounts of TGFBR2
mRNA expression in all of the cell lines transfected with the
ﬁve different constructs (unpublished data). In this analysis of
protein expression using the anti-FLAG antibody, we
demonstrated the expression of wild-type TGFBR2 protein
in cell lines transfected with TGFBR2(WT)-cDNA and
TGFBR2(WT)-splicing. We also demonstrated the expression
of truncated TGFBR2 protein in cell lines transfected with
TGFBR2( 1)-cDNA and TGFBR2( 1)-irrelevant. Intriguingly,
we could not detect any TGFBR2 protein in cell lines
transfected with TGFBR2( 1)-splicing, indicating a selective
translational repression of NMD-escape mutant mRNA
(Figure 3C).
PTC-Containing TGFBR2 mRNA Does Not Associate with
Polysomes
In order to conﬁrm that translational repression is
responsible for the failure to detect truncated protein from
PTC-containing TGFBR2 mRNA, we examined the mRNA
distribution of TGFBR2(WT)-splicing and TGFBR2( 1)-splic-
ing by polysome analysis.
In the cell line with the TGFBR2(WT)-splicing vector,
TGFBR2(WT)-splicing mRNA was found in the polysome-
containing fractions similar to endogenous GAPDH mRNA
(Figure 3D). However, in the cell line with the TGFBR2( 1)-
splicing vector, a greater percentage of TGFBR2( 1)-splicing
mRNA was found in the fractions that contained ribosomal
subunits and monosomes, whereas endogenous GAPDH
mRNA co-sedimented with polysomes (Figure 3E). Further-
more, upon the treatment of puromycin, a greater percent-
age of TGFBR2(WT)-splicing mRNA and endogenous
GAPDH mRNA were shifted into ribosomal subunits and
monosome-containing fractions (Figure 3F). In order to rule
out the possibility that the weak polysome association of
TGFBR2( 1)-splicing mRNA is due to its shorter open
reading frame as compared to the TGFBR2(WT)-splicing
mRNA, we repeated the same experiment using the
TGFBR2( 1)-splicing vector with puromycin treatment. The
results show that there is no signiﬁcant difference in the cell
line transfected with TGFBR2( 1)-splicing after puromycin
treatment (Figure 3E and 3G). These results indicate that (1)
the sedimentation of TGFBR2(WT)-splicing mRNA in heavy
fractions was due to polysome association, and (2) the shift of
TGFBR2( 1)-splicing mRNA into ribosomal subunits and
monosome-containing fractions is due to translational
repression, similar to TGFBR2(WT)-splicing mRNA and
TGFBR2( 1)-splicing mRNA treated with puromycin (Figure
3E–3G). This novel mechanism, whereby PTC recognition
itself triggers translational repression, is referred to as
nonsense-mediated translational repression (NMTR).
Factors Involved in Translational Repression of NMD-
Escape Mutant mRNA
We demonstrated the selective translational repression of
the NMD-escape mutant TGFBR2( 1)-splicing mRNA after
normal splicing, and this repression was not found in the
NMD-irrelevant mutant TGFBR2 mRNA, which lacks a
downstream sequence of the termination codon. Therefore,
we examined other possible factors inﬂuencing the expres-
sion of the truncated protein by: (1) changing the 39 UTR
length (the length between the PTC and poly(A) tail) to check
the possible effect of 39 UTR length on translational
repression [16], (2) treating with a proteasome inhibitor
(MG132) in the cell lines transfected with TGFBR2( 1)-
splicing and TGFBR2( 1)-irrelevant to rule out that the
truncated proteins are generated but rapidly degraded by the
proteasome, and (3) down-regulating key NMD factors, UPF1
and UPF2, to evaluate whether NMD factors are involved in
Figure 2. Western Blotting Analysis of NMD-Sensitive and NMD-Escape
Proteins
Truncated proteins were not detected in NMD-sensitive (hRad50 and
hMSH6) genes, whereas wild-type proteins were detected in the cell lines
containing the wild-type allele. In the NMD-escape hMSH3 gene, wild-
type hMSH3 proteins were detected in the cell lines containing the wild-
type allele. However, no truncated proteins of hMSH3 were detected in
the cell lines with frameshift mutation. GAPDH was used as a loading
control. The single asterisk indicates mutation status of each gene: ( 1)
denotes a 1-bp deletion in the cMNR, (w) denotes no mutation in the
cMNR, and (þ1) denotes 1-bp insertion in the cMNR. The double asterisk
indicates frameshift mutations of the other coding regions present in
both alleles of DLD-1 [38]. The dagger indicates that the expected size of
the truncated protein is indicated by the arrow.
doi:10.1371/journal.pbio.0050109.g002
PLoS Biology | www.plosbiology.org May 2007 | Volume 5 | Issue 5 | e109 1101
Nonsense-Mediated Translational RepressionFigure 3. Transfection Assay of the TGFBR2 Vector
(A) Schematic diagram of construct K (TGFBR2 wild-type cDNA), construct L (TGFBR2( 1)-deleted cDNA), construct M (TGFBR2 wild-type genomic DNA),
construct N (TGFBR2( 1)-deleted genomic DNA), and construct O (TGFBR2( 1)-deleted genomic DNA with a PTC artificially located in the last exon).
(B) Analysis of TGFBR2 mRNA by Northern blotting. The abundant expression of TGFBR2 mRNAs from the transfected constructs is shown. b-Actin was
used as a RNA loading control. Con. denotes the control vector pSecTag2B.
(C) Western blotting using anti-FLAG. Protein expression of transfected TGFBR2 constructs. Cell lines transfected with the constructs K and M expressed
wild-type TGFBR2. Cell lines transfected with the constructs L and O expressed truncated TGFBR2. However, cell lines transfected with construct N did
not express truncated TGFBR2, indicating translational repression after normal splicing. Con. denotes the control vector pSecTag2B. Enhanced green
fluorescent protein (EGFP) was used as a transfection control.
(D) Sucrose gradient fractionation of cytoplasmic extracts from cells expressing TGFBR2(WT)-splicing mRNA.
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spliced TGFBR2 mutant mRNA.
In order to change the 39 UTR length, we constructed
another TGFBR2( 1)-irrelevant with a full-length cDNA
sequence spanning from the PTC to the 39 end of TGFBR2
(P: TGFBR2( 1)-irrelevant-F) (Figure 4A). When the genomic
DNAs of TGFBR2( 1)-splicing, TGFBR2( 1)-irrelevant, and
TGFBR2( 1)-irrelevant-F were transfected, normal splicing
and a large amount of mutant mRNAs were present in all
three cell lines transfected with the different genomic DNAs
(Figure 4C). However, no proteins were expressed in the cell
lines transfected with TGFBR2( 1)-splicing, whereas a large
amount of truncated proteins were expressed in the cell lines
transfected with TGFBR2( 1)-irrelevant. In the cell lines
transfected with TGFBR2( 1)-irrelevant-F, the amount of
truncated proteins was reduced to about 35% of that of the
cell lines transfected with TGFBR2( 1)-irrelevant. These
ﬁndings indicate that the 39 UTR length itself or speciﬁc
cis-acting element(s) within the 39 UTR seem to contribute to
the translational inhibition of TGFBR2( 1) mRNA. However,
more importantly, a splicing event downstream of the PTC
may be involved in NMTR because truncated proteins are
(E) Sucrose gradient fractionation of cytoplasmic extracts from cells expressing TGFBR2( 1)-splicing mRNA.
(F) TGFBR2(WT)-splicing transfected cells were treated with puromycin prior to lysis and fractionation.
(G) TGFBR2( 1)-splicing transfected cells were treated with puromycin prior to lysis and fractionation.
In (D, E, F, and G), RNA extracted from each fraction was subjected to RT-PCR. Endogenous GAPDH mRNA was used as a control. TGFBR2(WT) mRNA was
found in the polysome-containing fractions similar to endogenous GAPDH mRNA. However, a greater percentage of PTC-containing TGFBR2( 1) mRNA
was found in the fractions containing ribosomal subunits and monosomes. The plots denote quantitative representation of TGFBR2 mRNA distribution
in polysome gradients. Relative mRNA levels in each fraction were calculated as a percentage of the total. Results from two independently performed
experiments did not vary, and the plot represents the average of the two independent experiments.
doi:10.1371/journal.pbio.0050109.g003
Figure 4. Both 39 UTR and Splicing Are Important for Translational Suppression of PTC-Containing TGFBR2 mRNA
(A) Schematic diagram of constructs P (NMD-irrelevant-type TGFBR2( 1)-deleted construct containing a full coding sequence), O, and N.
(B) Western blotting using anti-UPF1, anti-UPF2, or as a loading control, anti-GAPDH.
(C) Analysis of TGFBR2 mRNA by Northern blotting. The abundant expression of TGFBR2 mRNAs from the transfected constructs is shown. b-Actin was
used as a RNA loading control.
(D) Protein expression of transfected TGFBR2 constructs. Truncated proteins are not expressed in the cell lines transfected with TGFBR2( 1)-splicing,
whereas, truncated proteins are expressed by cell lines transfected with TGFBR2( 1)-irrelevant and TGFBR2( 1)-irrelevant-F. The amount of truncated
protein from the TGFBR2( 1)-irrelevant-F is approximately 35% of TGFBR2( 1)-irrelevant, indicating that the 39 UTR length or cis-element(s) affect
translational efficiency. Truncated proteins are not detected from cell lines transfected with TGFBR2( 1)-splicing when treated with MG132, a
proteasome inhibitor. Truncated proteins are not generated from cell lines transfected with TGFBR2( 1)-splicing when UPF1 and UPF2 are knocked
down by siRNA, indicating that UPF1 and UPF2 do not have an important role in the translational repression of TGFBR2( 1)-splicing mRNA. Enhanced
green fluorescent protein (EGFP) was used for transfection control. Con. denotes the control vector pSecTag2B. Luci denotes luciferase siRNA.
doi:10.1371/journal.pbio.0050109.g004
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but not in cells transfected with TGFBR2( 1)-splicing (Figure
4D).
We excluded the possibility that mutated proteins are
generated, but then rapidly degraded by the proteasome,
because cell lines transfected with TGFBR2( 1)-splicing and
treated with MG132, a proteasome inhibitor, demonstrated
no truncated proteins. In contrast, the cell lines transfected
with TGFBR2( 1)-irrelevant-F and treated with MG132
demonstrated similar amounts of truncated proteins com-
pared to cell lines only transfected with TGFBR2( 1)-
irrelevant-F (Figure 4D).
Finally, we evaluated whether key NMD factors are involved
in NMTR. We expected that the most signiﬁcant difference
between PTC-containing TGFBR2 mRNA and PTC-contain-
ing TGFBR2 mRNA, which lacks an intron downstream of the
PTC, would be the presence of exon junction complexes
(EJCs) behind the PTC. An EJC recruits the NMD factors,
UPF1 and UPF2, which play a key role in mRNA quality
control. We treated cells with UPF1 and UPF2 siRNA in order
to elucidate whether these two NMD factors are involved in
NMTR. The level of UPF1 was down-regulated to about 20%
of normal, where normal is deﬁned as the level in the
presence of the nonspeciﬁc control, luciferase siRNA, where-
as the level of UPF2 was down-regulated to about 10% of
normal (Figure 4B). Treatment of any of the siRNAs failed to
produce truncated proteins in the cell lines transfected with
TGFBR2( 1)-splicing, indicating that at least these two NMD
factors do not play an important role in the NMTR of NMD-
escape mutant TGFBR2 mRNA (Figure 4D).
NMD-Irrelevant Mutant mRNA of MARCKS Generates
Truncated Proteins
We then examined whether NMD-irrelevant PTC-contain-
ing mRNA can generate truncated protein. We selected one
NMD-irrelevant mRNA, mutant MARCKS, and performed a
transfection assay using wild-type MARCKS genomic DNA
(MARCKS(WT)-splicing) and mutant MARCKS genomic DNA
with a 2-bp deletion (MARCKS( 2)-splicing) (Figure 5A).
We found expression of wild-type and truncated protein in
cell lines transfected with MARCKS(WT)-splicing and
MARCKS( 2)-splicing, respectively, by Western blotting with
an anti-FLAG antibody (Figure 5B). To verify that these
protein products were identical to MARCKS, we performed
Western blotting with the anti-MARCKS antibody and
conﬁrmed the expression of wild-type and truncated proteins
(Figure 5C). We also found that the truncated MARCKS
protein is subject to active proteasome-mediated degrada-
tion; the amount of truncated MARCKS protein increased
with time when cells were treated with MG132, a proteasome
inhibitor (Figure 5B and 5C).
Discussion
In this study, we found that some PTC-containing mRNAs
are not degraded by the NMD system, and their protein
Figure 5. Truncated Protein Expression from Mutant NMD-Irrelevant MARCKS mRNA
(A) Schematic diagram of construct Q (MARCKS wild-type genomic DNA) and construct R (MARCKS( 2) deleted genomic DNA).
(B) Western blotting (WB) analysis of total protein (30 lg) isolated from transiently transfected cell lines with constructs Q or R. An antibody against
FLAG was used as the primary antibody.
(C) Western blotting (WB) analysis of total protein (30 lg) isolated from transiently transfected cell lines with the constructs Q or R was performed using
an antibody against MARCKS. Enhanced green fluorescent protein (EGFP) was used as a control for transfection efficiency. Comparable results were
obtained in at least two independent experiments. Asterisks (*) denote endogenous MARCKS reacted with anti-MARCKS antibody; Con. denotes the
control vector pcDNA3.1(þ). The dagger indicates uncharacterized protein that did not interfere with experimental interpretations.
doi:10.1371/journal.pbio.0050109.g005
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Nonsense-Mediated Translational Repressiontranslations are repressed. We therefore suggest that PTC-
containing mRNAs resulting from frameshift mutations can
be classiﬁed into three groups: NMD-sensitive mRNAs, which
are degraded by the NMD system; NMD-escape mRNAs,
w h i c ha r en o td e g r a d e db yt h eN M Ds y s t e m ,b u td o
experience repression of protein expression; and NMD-
irrelevant mRNAs, which are not recognized by the NMD
system, and generate truncated proteins. Our ﬁndings
indicate that both NMD and NMTR, an additional surveil-
lance mechanism for translational control, are involved in the
recognition of PTC and suppression of truncated protein
from PTC-containing genes that can be deleterious to cell
function (Figure 6).
NMD is a quality control-based surveillance mechanism
that protects cells from the potentially dominant negative
effects of truncated mutant proteins. The primary role of the
NMD pathway is to eliminate nonsense transcripts that result
from faulty transcription, alternative splicing, or somatic
mutation [17,18]. This pathway selectively degrades mRNAs
that prematurely terminate translation due to a frameshift or
nonsense mutation. Although NMD is a quality control-based
surveillance mechanism, avoidance of NMD by PTC-contain-
ing mRNAs has been reported for the mutated genes of many
diseases. Moreover, about one third of the alternative
transcripts in cells are expected to contain PTCs due to
splicing errors and regulated unproductive splicing and
translation (RUST). Some of these PTC-containing mRNAs
belong to the NMD-escape variety [14,15]. If translated, these
NMD-escape mRNAs could produce truncated proteins that
may critically interfere with cell viability. Among the PTC-
containing mRNAs, some PTCs, which are called NMD-
irrelevant mRNAs, are located within 50–55 nt or down-
stream of the last exon–exon junction and are not detected
by NMD. Proteins generated from these types of PTC-
containing mRNAs and their causal relationship to speciﬁc
diseases have been well documented [19–21]. However, there
are no reports describing translated proteins from mutation-
derived NMD-escape mRNAs, although many NMD-escape
PTC-containing mRNAs have been reported [22–24].
In this study, we demonstrated that NMD-escape TGFBR2
mRNA is subject to NMTR. Our transfection study of TGFBR2
constructs demonstrated that PTC-containing mRNAs from
mutant TGFBR2 were abundant after transfection of mutant
cDNA and mutant TGFBR2 genomic DNAs with a 1-bp
deletion. However, truncated proteins were only detected in
the cell lines transfected with mutant TGFBR2 cDNA, and no
truncated proteins were detected in the cell lines transfected
with mutant TGFBR2 genomic DNAs with a 1-bp deletion. In
contrast, strong expression of TGFBR2 protein was observed
in the cell lines transfected with wild-type TGFBR2 genomic
Figure 6. Schematic Model for the Functional Consequences of the Three Classes of PTC-Containing mRNAs
NMD-sensitive mRNAs are degraded by the NMD system. NMD-escape mRNAs are not degraded by the NMD system, but experience repression of
protein expression. NMD-irrelevant mRNAs are not recognized by the NMD system and generate truncated proteins.
doi:10.1371/journal.pbio.0050109.g006
PLoS Biology | www.plosbiology.org May 2007 | Volume 5 | Issue 5 | e109 1105
Nonsense-Mediated Translational RepressionDNA. Next, we conﬁrmed using polysome analysis that the
lack of truncated protein translated from PTC-containing
TGFBR2 mRNA is due to translational repression, not
instability of TGFBR2 mRNA.
The major expected differences between the two PTC-
containing TGFBR2 mutant mRNAs and mRNA from the
cDNA of TGFBR2 or TGFBR2 genomic DNA are the
deposition of the EJC and the possible recruitment of NMD
factors to the mRNA during translation termination. We also
conﬁrmed the NMTR by demonstrating that mutant mRNA
and truncated proteins were efﬁciently expressed in the cell
line transfected with mutant TGFBR2 genomic DNA con-
taining a PTC in the last exon without downstream introns
(Figures 3C and 4D). We therefore suspected that EJC
proteins and/or NMD factors might play an important role
in the NMTR. It is well known that NMD recognizes PTC and
downstream splicing events that deposit an EJC at an exon–
exon junction. The EJC is composed of proteins involved in
splicing and the subsequent steps of mRNA transport and
translation. EIF4A3, RNPS1, Y14, and MAGOH are involved
in EJC formation, and the EJC–mRNA complex is then
exported to the cytoplasm together with nuclear cap binding
proteins CBP80/20 and nuclear poly(A) binding protein 2
(PABP2) [25–28]. The mRNA then recruits UPF2 and under-
goes a so-called ‘‘pioneer’’ round of translation during mRNA
export. NMD occurs when translation terminates more than
50–55 nt upstream of the last exon–exon junction. Transient
SURF formation at the termination codon, which is com-
posed of Smg1, UPF1, and translation termination factors
eRF1–eRF3, is thought to interact with the downstream EJC
so as to trigger phosphorylation of UPF1 and thereby elicit
NMD [26–30]. In this study, we demonstrated that key NMD
factors, UPF1 and UPF2, did not play an important role in the
NMTR, which is evidenced by the fact that treatment of UPF1
and UPF2 siRNA did not produce truncated proteins in cell
lines transfected with TGFBR2( 1)-splicing, even though both
siRNAs drastically down-regulate endogenous UPF1 and
UPF2. Moreover, down-regulating Y14 or EIF4A3, which are
EJC components, using siRNA failed to restore translational
repression of TGFBR2( 1)-splicing (unpublished data). Our
results indicate that NMTR is at work on the NMD-escape
PTC-containing TGFBR2 mRNA by some unknown surveil-
lance mechanism. The involvement of another messenger
ribonucleoprotein particle (mRNP) complex in this transla-
tional repression is essentially unknown. Future studies
should be focused on the role of translational repression of
the various RNA binding proteins in the PTC-containing
mRNP complex.
Several recent reports have demonstrated the importance
of termination codon context, especially 39 UTR length, in
PTC recognition [16]. Therefore, we tested two TGFBR2( 1)-
irrelevant vectors with short and extended 39 UTR lengths. If
the PTC-containing, 39 UTR-extended construct failed to
produce truncated protein, then unlike NMD, splicing and
EJCs may not be involved in the mechanism of NMTR. In this
experiment, we demonstrated a 65% reduction of truncated
p r o t e i ni nt h ec e l ll i n e st r a n s f e c t e dw i t hT G F B R 2 (  1)-
irrelevant vector with an extended 39 UTR length. These
ﬁndings indicate that 39 UTR length is an important factor;
however, other important factors are involved in NMTR.
Because NMTR depends on 39 UTR length or a putative cis-
element residing in the 39 UTR, it is, in part, reminiscent of
EJC-independent NMD. A PTC within the penultimate exon
of the b-globin or TPI gene elicits NMD depending on the
position of PTC relative to the last EJC [12,31]. However, for a
PTC within the penultimate exon that normally elicits NMD,
deleting the last intron fails to eliminate NMD, indicating
that the last exon has a so-called ‘‘failsafe’’ sequence that
allows for PTC recognition and triggers NMD in the absence
of a downstream EJC. Intriguingly, this element requires that
splicing occur upstream of the PTC because the PTC-
containing mRNA that is derived from an intronless TPI or
b-globin gene is immune to NMD [12]. It remains to be
clariﬁed whether NMTR also requires a splicing event
upstream of the PTC. Recently, another case for EJC-
independent NMD has been reported in immunoglobulin-l
mRNA [16]. Similar to NMTR, EJC-independent NMD of this
mRNA depends on the 39 UTR length. However, the mode of
PTC recognition looks quite different between NMTR and
EJC-independent NMD of this mRNA, in the sense that
NMTR does not require the NMD factors, UPF1 and UPF2, as
shown in our study. Important questions of whether mRNAs
targeted by EJC-independent NMD are subject to NMTR
should be addressed.
Marked degradation of PTC-containing mRNAs and
decreased protein synthesis from PTC-containing mRNAs
by the NMD system have been reported in yeast [32]. Another
important mRNA surveillance mechanism, nonsense-medi-
ated altered splicing (NAS), has been reported in mammalian
cells [33]. NAS induces alternative splicing in the PTC-
containing mRNA, thus avoiding the production of toxic
mutant proteins. Although the exact mechanism of NAS had
not been reported, UPF1 plays an important role in NAS [34].
Together with our ﬁndings that UPF1 did not play a
signiﬁcant role in NMTR, all of these ﬁndings indicate that
(1) NMD, NAS, and NMTR play important roles in the
inhibition of deleterious mutant protein production, and (2)
unlike NMD and NAS, UPF1 and UPF2 do not a play key role
in NMTR, suggesting novel factor(s) or pathways exist in the
NMTR.
In conclusion, we demonstrated three different molecular
pathways of PTC-containing mRNAs. We propose a novel
mechanism of gene expression regulation for PTC-containing
mRNAs, in which the deleterious transcripts are regulated
either by NMD or NMTR. Future studies of the NMD and
NMTR control mechanism will enable us to better under-
stand the reason for speciﬁc protein expression among the
numerous mRNA isoforms, as well as the selective cellular
control mechanism of protein expression.
Materials and Methods
Cells and media. Ten cell lines were obtained from either the
American Type Culture Collection (ATCC; http://www.atcc.org) or the
Korean Cell Line Bank (KCLB; http://cellbank.snu.ac.kr). Seven cell
lines (LS174T, HCT-8, SNU C2A, SNU C4, DLD-1, HCT116, and
LOVO) were MMR-deﬁcient, and three (NCI-H508, SW480, and
HT29) were MMR-proﬁcient in terms of their MSI status, as
determined by previous studies [35,36]. We conﬁrmed the presence
of MSI using BAT26 and BAT25 markers. Cells were grown in RPMI
supplemented with 10% FBS (Life Technologies, Grand Island, New
York, United States), penicillin, and streptomycin at 37 8Ci n5 %C O 2.
Identiﬁcation of MSI and frameshift mutations of target genes.
Genomic DNA and cDNA preparation, analysis of MSI, and
identiﬁcation of target gene frameshift mutations were performed
as described previously [37].
NMD inhibition by puromycin treatment. We used puromycin
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proteins involved in NMD. Cells were grown to 80% conﬂuence and
then treated with 30-lg/ml puromycin. Six hours later, the cells were
harvested, and total RNA was isolated using an RNeasy Mini kit
(QIAGEN, Valencia, California, United States) according to the
manufacturer’s instructions.
UPF1 and UPF2 targeting by siRNAs. Twenty-one–nucleotide
RNAs were chemically synthesized using a Silencer siRNA Construc-
tion kit (Ambion, Austin, Texas, United States). Synthetic oligonu-
cleotides were deprotected and gel-puriﬁed. HCT116 and SNU C2A
cells growing in six-well dishes were transfected with 50 nM siRNA
and oligofectamine (Invitrogen, Carlsbad, California, United States)
according to the manufacturer’s protocol. For RT-PCR analysis, total
RNA was harvested 48 h after siRNA transfection. Targeted
nucleotides, numbered relative to the start codon, were as follows:
rent1/UPF1, 1,879–1,901 (59-AAGATGCAGTTCCGCTCCATTTT-39);
rent2/UPF2, 1,423–1,445 (59-AAGGCTTTTGTCCCAGCCATCTT-39);
and luciferase GL2, 153–173 (59-AACACGTACGCGGAATACTTCGA-
39). The inhibition of UPF1 and UPF2 expression by siRNA targeting
was evaluated by semi-quantitative RT-PCR or Western blotting.
Construction of TGFBR2 and MARCKS expression vectors. To
study expression of TGFBR2, we selected the secreted expression
vector, pSecTag2B (Invitrogen). The vector was cut by Hind III, and
the FLAG oligonucleotide was inserted into the Hind III site to allow
for speciﬁc immunodetection, thereby creating the pSecTag-FLAG
vector. The complete coding sequence of full-length TGFBR2 begins
with the ﬁrst ATG at codon 1 and encodes a 568–amino acid protein,
with a stop codon at 569. Mutant TGFBR2 with a 1-bp deletion at ten
adenosine repeats results in a premature stop at codon 162 (Figure
S1). We constructed wild-type (constructs K and M) and truncated
TGFBR2 expression vectors (constructs L, N, O, and P).
Wild-type TGFBR2 cDNA was obtained from a 293T cell line and
mutant (1-bp deletion) TGFBR2 cDNA was obtained from a HCT116
cell line by RT-PCR and then cloned using a T&A cloning kit (RBC,
Taipei, Taiwan). Construct K (TGFBR2(WT)-cDNA) and construct L
(TGFBR2( 1)-cDNA) were generated by inserting the Hind III
fragment from the TGFBR2 cDNA into the Hind III site of
pSecTag-FLAG.
In order to analyze splicing and subsequent protein expression, we
inserted wild-type and mutant TGFBR2 genomic DNA into the
expression vectors. To generate constructs M (TGFBR2(WT)-splicing)
and N (TGFBR2( 1)-splicing), exons 1 to 7, except exon 3, of TGFBR2
were obtained by PCR using 293T cell genomic DNA and cloned into
the yT&A cloning vector (RBC). Exon 3 of TGFBR2 was obtained from
LOVO and 293T DNA by PCR, because a 1-bp deletion in the cMNR
exists in exon 3 of TGFBR2 in LOVO. All primers for cloning were
designed to contain more than 100 bp of intron sequence on each
side of the exon boundary to ensure accurate splicing of the
construct. These exon fragments were ligated to each other using a
restriction enzyme site in the multiple cloning site (MCS) of the yT&A
vector. In the case of exon 1, deletion of the signal peptide was
performed using Dpn1 for N-terminal FLAG tagging. The ligated
genomic construct of TGFBR2 was inserted into the pSecTag-FLAG
vector. To generate construct O (TGFBR2( 1)-irrelevant), exon 4 to
exon 7 of TGFBR2( 1)-splicing was deleted by cutting with BstX1,
and the remaining construct was self-ligated. To generate construct P
(TGFBR2( 1)-irrelevant-F), cDNA from exon 4 to exon 7 of TGFBR2
was inserted into the pSecTag-FLAG vector using EcoR1 and Pst1
restriction enzyme sites, and then genomic DNA from exon 1 to exon
3 was inserted into the same vector using the BamH1 restriction
enzyme site.
For the expression study of MARCKS, the expression vector
pcDNA3.1(þ) (Invitrogen) was cut by Hind III, and the FLAG
oligonucleotide was inserted at the Hind III site to allow for speciﬁc
immunodetection, thereby creating the pcDNA-FLAG vector. In
order to analyze splicing and subsequent protein expression, we
inserted wild-type and mutant MARCKS genomic DNA into
expression vectors. To generate constructs P (MARCKS(WT)-splicing)
and Q (MARCKS( 2)-splicing), exon 1 of MARCKS was obtained
through PCR using genomic DNA of 293T and cloned into the yT&A
cloning vector (RBC). Exon 2 of MARCKS was obtained from SNU
C2A by PCR, since 2-bp monoallelic deletions in the cMNR exist in
exon 2 of MARCKS in SNU C2A. These exon fragments were
subcloned into the expression vector pcDNA-FLAG. Primer sequen-
ces are shown in Table S3.
Transfection. HCT116 and HeLa cells (2 3 10
6) were transiently
transfected using Lipofectamine 2000 (Invitrogen) with the speciﬁc
construct plasmid and pSecTag-FLAG vector in a 60-mm plate. Cells
were harvested 2 d later. Protein was puriﬁed from half of the cells
using passive lysis buffer (Promega, Madison, Wisconsin, United
States), and total RNA was puriﬁed from the other half using TRIzol
Reagent (Invitrogen).
Western blotting. Whole lysates from cell lines were prepared
using passive lysis buffer (Promega). Thirty micrograms of the total
protein lysates were loaded into each lane, size-fractionated by SDS-
PAGE, and then transferred to a PVDF membrane that was blocked
with TBST containing 5% skim milk. Primary antibodies against
GAPDH (Trevigen, Gaitherburg, Maryland, United States), FLAG
(Sigma-Aldrich), hRad50 (Ab13B3; Gene Tex), MARCKS (Santa Cruz
Biotechnology, Santa Cruz, California, United States), or hMSH6 and
hMSH3 (BD Bioscience, Mountain View, California, United States)
were incubated for 1 h at room temperature. After washing,
membranes were incubated with HRP-conjugated secondary anti-
body (Santa Cruz Biotechnology), washed, and then developed with
ECL-Plus (Amersham Pharmacia Biotech, Little Chalfont, United
Kingdom).
RPA. RNA samples were extracted from each cell line using TRIzol
Reagent (Invitrogen). RPA was carried out according to the
instructions provided by the manufacturer (RiboQuant RPA kit; BD
Biosciences) using 20 lg of total RNA per sample. The template
antisense
32P-labeled RNA probes were speciﬁc for TGFBR2
(unprotected, 271 nt; protected, 254 nt), hRad50 (371, 353), hMSH6
(332, 312), and GAPDH (134, 120) mRNA. GAPDH was used as an
internal control. The intensity of speciﬁc bands corresponding to
individual riboprobes was determined by densitometry. All RPAs
were evaluated at different exposures, and only bands that were
within the linear range of the ﬁlm were analyzed.
Northern blotting. Total RNA was extracted from HCT116 with
TRIZOL Reagent (Invitrogen). Full-length TGFBR2 cDNA was
ampliﬁed by RT-PCR using 293T total RNA. Expression of the
exogenous TGFBR2 construct mRNA was analyzed by Northern blot
analysis using 10 lg of total RNA according to standard protocols.
Polysome assay. Cultures were supplemented with 100-lg/ml
cycloheximide for 24 h post-transfection and incubated for 5 min
at room temperature. HeLa cells were washed three times with ice-
cold PBS containing 100-lg/ml cycloheximide. HeLa cells were
collected by scrapping in PBS, transferred to Eppendorf tubes for
additional washes, and then lysed in lysis buffer (15 mM Tris-Cl [pH
7.4], 3 mM MgCl2, 10 mM NaCl, 0.5% Triton X-100, 100-lg/ml
cycloheximide, 1-mg/ml heparin, and 200 U RNasin [Promega]). When
indicated, puromycin (100 lg/ml) was added to the cultures 2 h prior
to harvesting, and cycloheximide was omitted from the gradient. For
each construct, lysates from two 100-mm dishes were pooled into a
microcentrifuge tube and incubated for 10 min on ice with
occasional mixing. Nuclei and debris were removed by centrifugation
at 12,000g for 2 min. Then, 1 ml of each cytoplasmic lysate was layered
onto an 11-ml 10%–50% sucrose gradient and centrifuged at 4 8Ci n
an SW40 rotor (39,000 rpm) for 2 h. Sixteen fractions were collected
from the top with concomitant measurement of absorbance at 254
nm, using a fraction collection system. RNA was extracted with
TRIZOL Reagent and analyzed by RT-PCR.
Supporting Information
Figure S1. A Schematic Diagram Shows Formation of a Premature
Termination Codon Resulting from Frameshift Mutation
Schematic diagram of the PTC formation derived from frameshift
mutation in the MSI-H tumors. These frameshift mutations generate
neo-amino acid sequences in the C-terminal part of the proteins and
formation of premature termination codon, respectively.
Found at doi:10.1371/journal.pbio.0050109.sg001 (1.8 MB JPG).
Figure S2. Expression Proﬁle of Premature Termination Codon-
Containing mRNAs
Analysis of frameshift mutations and mRNA expression proﬁles of
TGFBR2, hRad50, and hMSH6 in seven MMR-deﬁcient and three
MMR-proﬁcient colorectal cancer cell lines. PCR primers were
designed to contain mononucleotide repeats of each gene. Frameshift
mutations are discovered by a change in length of ampliﬁed products
due to either the insertion or deletion of mononucleotide repeat
units of each gene. Fragments of shifted bands (arrowhead) from
three target genes are shown in seven MMR-deﬁcient colorectal
cancer cell lines by PCR using genomic DNA. In the RT-PCR, TGFBR2
showed identical mutant transcripts in the seven MMR-deﬁcient
colorectal cancer cell lines, whereas a total loss of the hRad50 and
hMSH6 mutant transcripts was seen in the same seven MMR-deﬁcient
colorectal cancer cell lines. All undetected mutant transcripts
reappeared when cells were treated with puromycin. A ﬁlled triangle
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Nonsense-Mediated Translational Repression(m) indicates a shifted band from a 1-bp deletion mutation; a ﬁlled
inverted triangle (.) indicates a shifted band from a 1-bp insertion
mutation.
Found at doi:10.1371/journal.pbio.0050109.sg002 (1.0 MB JPG).
Figure S3. Detection of Frameshift Mutant hRad50 and hMSH6
Transcripts after NMD Inhibition
(A) Effects of siRNA treatment on HCT116 and SNU C2A cell lines.
HCT116 and SNU C2A cells were transfected with siRNA duplexes
directly against UPF1, UPF2, and ﬁreﬂy luciferase (negative control).
Seventy-two hours after transfection, cells were harvested and RNAs
were extracted. Markedly reduced expressions of UPF1 and UPF2
were noted by semi-quantitative RT-PCR. b-actin was used as a
control.
(B) Frameshift mutation proﬁles of hRad50 and hMSH6 were revealed
in HCT116 and SNU C2A colorectal cancer cell lines. PCR primers
were designed to contain mononucleotide repeats of each gene.
Frameshift mutations are discovered by a change in length of
ampliﬁed products due to either the insertion or deletion of
mononucleotide repeat units of each gene. The HCT116 cell line
has a heterozygous deletion of an adenine in the (A)9 repeats of
hRad50 and a heterozygous deletion of a cytosine in the (C)8 repeats
of hMSH6. The SNU C2A cell line has a heterozygous insertion of an
adenine in the (A)9 repeats of hRad50 and a homozygous insertion of
a cytosine in the (C)8 repeats of hMSH6.
(C) Frameshift mutant transcripts of hRad50 and hMSH6 were not
detected in HCT116 and SNU C2A cell lines. The mutant transcripts
appeared when the cell lines were treated with UPF1 and UPF2
siRNA.
(D) Sequence chromatograms of the shifted bands from hRad50 (ﬁlled
triangle [m]) and hMSH6 (ﬁlled inverted triangle [.]) show the
deletion of one adenine in the hRad50 (A)9 repeats, and the insertion
of one cytosine in the hMSH6 (C)8 repeats, respectively. A ﬁlled
triangle (m) indicates a shifted band from a 1-bp deletion of hRad50
mRNA; a ﬁlled inverted triangle (.) indicates a shifted band from a 1-
bp insertion of hMSH6 mRNA; Luci, Luciferase.
Found at doi:10.1371/journal.pbio.0050109.sg003 (1.4 MB JPG).
Figure S4. Western Blotting Analysis of NMD-Escape Proteins from
hMSH3
hMSH3 wild-type proteins were detected in the cell lines containing
wild-type alleles. However, no truncated proteins of hMSH3 were
detected in the cell lines with frameshift mutation. The hMSH3
antibody detected the truncated proteins from the cell lines trans-
fected with mutant hMSH3 cDNA, indicating that antibodies used in
our experiments speciﬁcally react with the N-terminal region of
hMSH3 protein. GAPDH was used as a loading control.
*Mutation status of each gene: ( 1) denotes a 1-bp deletion in the
cMNR, (w) denotes no mutation in the cMNR, and (þ1) denotes a 1-bp
insertion in the cMNR. Control denotes the HeLa cell line transfected
with mutant hMSH3 cDNA vector.
Found at doi:10.1371/journal.pbio.0050109.sg004 (562 KB JPG).
Table S1. Frameshift Mutation Status of NMD Target Genes in
Colorectal Cancer Cell Lines
Found at doi:10.1371/journal.pbio.0050109.st001 (53 KB DOC).
Table S2. Primers of the 13 Genes Used for RT-PCR Analysis
Found at doi:10.1371/journal.pbio.0050109.st002 (38 KB DOC).
Table S3. Primers of the TGFBR2 and MARCKS Used for Cloning
Found at doi:10.1371/journal.pbio.0050109.st003 (35 KB DOC).
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